Nutraceutical longevity brand SRW Laboratories announced it has joined forces with a leading clinical stage artificial intelligence (AI) drug discovery company, Insilico Medicine.
The partnership aims to utilise AI technology to develop state-of-the-art longevity products, with the aim of extending healthspan.
While numerous diseases associated with advancing age were once seen as inevitable, they are increasingly being recognised as syndromes of cellular ageing. This paradigm shift has followed the investment of billions of dollars into geroscience – the study of the biology of ageing – intending to delay the onset of these conditions by slowing the breakdown of the cell.
The past decade has spurred substantial research breakthroughs, with scientists identifying numerous cellular pathways linked to ageing. The discovery of over 100 molecules with the potential to not just slow, but even reverse, the ageing trajectory has driven more interest and research into the longevity space. The integration of AI into the nutraceutical space allows SRW to combine the very best of science and technology to create new formulations with the potential for increased efficiency.
“Slowing aging and increasing the number of healthy years in our lives is at the forefront of our combined mission,” said SRW Founder, Greg Macpherson. “Our partnership with Insilico gives us the ability to screen tens of thousands of natural molecules and compounds, assessing their capabilities in promoting healthy aging and extending healthspan, at a speed never before available in the nutraceutical space. We are tremendously honoured to partner with them in this joint endeavour.”
Under the partnership, SRW will benefit from access to Insilico’s proprietary end-to-end Pharma.AI platform, which analyses massive quantities of data to find new connections between biological processes and disease, design new therapeutics, and predict the outcomes of clinical trials.
Insilico Medicine has raised over $400 million in funding from leading investors and partnered with numerous pharmaceutical companies, including a multi-target collaboration with Sanofi worth up to $1.2b. The global gains from decelerating ageing are enormous—an estimated $37 trillion for each added year of lifespan. Such accomplishments promise to bolster productivity, escalate economic spending, and alleviate the strain on healthcare systems.
“Aging is a universal issue, and one that we’re closer than ever to solving,” noted Alex Zhavoronkov, PhD, co-CEO and founder of Insilico Medicine. “We’ve been utilising our technology to increase output in the pharmaceutical space for years, but this is the first time we’re turning our attention to the natural supplement sector. We’re excited to help SRW make huge strides in analysing which compounds are the most effective and bring them to market. Extending the number of healthy years in a person’s life is a very motivating mission.”
By 2050, the global demographic will see 2 billion people over 60. Roughly half of this populace will grapple with costly health conditions impacting their productivity. Hence, the sprint to prolong healthspan and offer significant health benefits to individuals, families, communities, and nations is vital.
The introduction of AI is revolutionising the pace of development in this sector. Advanced AI allows for rapid drug discovery, where deep learning establishes robust frameworks. With this partnership, AI will be deployed to concentrate on natural products, already recognised for their efficacy and safety, and merge them to support healthspan extension.
The SRW and Insilico partnership represents a significant collaboration within the natural supplement category. The partnership is already active, and SRW hopes to unveil its first AI-assisted product suite in 2024.
Ritchelle is a Content Producer for Healthcare Channel, Australia’s premier resource of information for healthcare.
